# AuB

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aub

- Industry: Food
- Headquarters: Tokyo, Japan
- Website: www.aub.co.jp
- Total disclosed funding: $5.1M
- Latest round: Series B (Jun 1, 2022)
- Investors on record: 4

## About

Founded in 2015 and based in Tokyo, Japan, AuB Inc. focuses on developing gut microbiome solutions for athletes, utilizing extensive data on athlete gut health to enhance performance and wellness through innovative products, and  research-backed methodologies. The company specializes in microbiome health, particularly for athletes. The CEO is Keita Suzuki, leading the company in its mission to leverage advanced research in gut health.AuB???? specializes in the research and development of gut microbiome solutions tailored for athletes, emphasizing the importance of gut health through the 'aub gut care method.' Their core offerings include gut health supplements and analysis kits aimed at improving wellness for both professional athletes and the general public. These products are based on solid scientific research and are marketed mainly in Japan, with plans for international expansion.AuB???? generates revenue through direct-to-consumer sales of gut health supplements and analysis kits, which are marketed as premium products. The revenue model includes retail sales via the online store and subscription services for health monitoring. Collaborations with sports organizations enhance product integration into athlete support programs, reflecting a strategy focused on quality and health-conscious consumers. In?July 2025, AuB Inc. raised an undisclosed amount in venture funding?from new investor?Septeni Holdings. The company plans to use its proceeds from July 2025 to accelerate its D2C business, advance product development, broaden its customer base, and create services that support data-driven health management.

## Funding rounds

- Series B, Jun 1, 2022, $2.4M — Kyocera Corporation, Mitsubishi UFJ Capital, Shizuoka Capital, Taisho Pharmaceutical Co., Ltd.
- Series A, Sep 24, 2019, $2.8M — Mitsubishi UFJ Capital, Taisho Pharmaceutical Co., Ltd.

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B
- Taisho Pharmaceutical Co., Ltd. — Series A, Series B
- Kyocera Corporation — Series B
- Shizuoka Capital (https://capitalatlas.ai/funds/shizuoka-capital) — Series B